Daniel J. Nevrivy, Ph.D.
Daniel Nevrivy specializes in U.S. and international intellectual property procurement and enforcement with substantial expertise in the life sciences. He represents a global suite of life science innovators including startups, emerging firms, research universities, and global corporations.
He has successfully assisted clients for over 20 years securing and protecting their intellectual property assets. He has drafted and prosecuted hundreds of domestic and international patent applications that span the entire breadth of technologies found in the life sciences, including therapeutic antibodies and biologics, genome editing, artificial intelligence-based prognosis and treatment, gene therapy, immunotherapies, vaccines, diagnostics, therapeutic methods, small molecules, drug formulation and delivery technologies, cell therapies, stem cells and regenerative medicine, and therapeutic devices.
He has been involved in several IP due diligence audits on both the buy and sell sides of various transactions, including venture investment, licensing, and acquisition of intellectual property.
His practice further includes counseling pre-clinical and clinical stage life science corporations regarding intellectual property strategies and portfolio management. He has conducted numerous freedom-to-operate investigations; rendered numerous legal opinions regarding inventorship, patentability, non-infringement and invalidity of patents.
He has also represented a medical device company in a trademark infringement, breach of contract and defamation lawsuit in U.S. District Court and obtained judgment, damages and various sanctions of over 17M.
He also maintains an active pro bono practice representing disabled U.S. veterans in their IP matters who are graduates of the Entrepreneurship Boot Camp (EBV) program run by Syracuse University.
During his doctoral studies he investigated transcriptional regulation mediated by steroid/thyroid hormone receptors, especially the retinoic acid receptor (RAR) and studied RAR-induced cell differentiation of pluripotent embryonal carcinoma (EC) cells. He identified and cloned a novel gene product (Grasp) regulated by RARs in EC cells and conducted experiments to elucidate the biological function of the gene product. He also assisted in the cloning and characterization of the novel transcription factor genes Bcl11a and Bcl11b. A therapy targeting the Bcl11a gene recently won regulatory approval and became the world’s first approved therapy using CRISPR technology.
Some of his speaking engagements, media placements and publications include:
Pfizer is looking for its next blockbuster after Covid. Could one of them be treating cancer?, Times Square Investment Journal (November 2023)
U.S. IP Climate Change: Challenges and Opportunities for Biopharmas, 8th IP Pharma Forum, Shanghai (October 2023)
Alternative Career Options for Immunologists, American Association of Immunology Annual Meeting, Washington, D.C. (May 2023)
Strategies for Obtaining Biotech and Pharmaceutical Patents in the United States, Guangzhou, China (October 2019)
Cross-border Camp Talk: Strategic considerations for obtaining patents on your intellectual property assets, Vienna, Austria (March 2019)
5 Urgent Reasons For Patenting Your Regenerative Procedures, Regenerative Warrior Podcast (February 2019)
Recent Developments in Patent Eligibility, Divided Infringement, and Protection of Antibodies – Bethesda,Maryland, Intellectual Property Protection in Biopharmaceutical Industry (October 2018)
Moderated panel discussion entitled How to Grow your Startup IP practice at the 33rd Annual Intellectual Property Law Conference – American Bar Association (April 2018)
“The BPCIA Patent Dance – What Biosimilar Companies Need To Know,” The Knowledge Group Webcast, January 2017
Life Sciences Patent Attorney of the Year – Mid-Atlantic USA (Acquisition International 2017 Legal Awards)
US (DC) – Patent attorney of the year, ACQ Global Awards 2016
“Lawyers Offer Predictions for Myriad, Diagnostic Field Based on Supreme Court’s Decision Against Prometheus ” Genetic Engineering & Biotechnology News
“Intellectual Property – Some Business Considerations,” Symposium on Entrepreneurship – A Tool Kit for Launching a University Based Start-Up, University of Maryland BioPark.
“Life Science Patent Eligibility in the Midst of Myriad, Classen and Prometheus,” In-House Counsel Continuing Legal Education
Academic & Pharma Partnerships: Tapping the Ivory Tower for the Next Blockbuster, FiercePharma
“Caveats in Patent Overhaul Could Pose New Challenges for Smaller Biopharmas” Genetic Engineering & Biotechnology News
“Implementation of European Court Decision to Ban hESC Patents Depends on National Patent Offices” Genetic Engineering & Biotechnology News
“Asia’s Emerging Markets Catching Up to the U.S. and Europe in Terms of Innovation” Genetic Engineering & Biotechnology News
“The Myriad Genetics Ruling – was the global biotech industry gutted? “National Public Radio (Tech Nation)
“China gets serious about biotech” FierceBiotech
“Alkermes To Put Its Long-Acting Stamp On Trusted Blockbusters, Starting With Abilify,” “The Pink Sheet,” Elsevier, February 2010
“Saving Roman” – a video about the childhood cancer neuroblastoma produced by the Biotechnology Industry Organization (BIO) and showcased at the 2009 BIO International Convention keynote luncheon
“Expert in Patent Law in the Life Sciences Provides Insight on Today’s Market and the Outlook for the Future of Biotech and Pharma Companies,” Life Science Executive Exchange
“Restoring Science to its Rightful Place in America,” IPLaw360
“Does the U.S. biotech industry deserve a bailout?” FiercePharma and FierceBiotech
Venkataraman et al., Grp1-associated scaffold protein regulates skin homeostasis after ultraviolet irradiation, Photochem Photobiol Sci. 13:531-40 (2014)
Venkataraman et al., Grp1-associated scaffold protein (GRASP) is a regulator of the ADP ribosylation factor 6 (Arf6)-dependent membrane trafficking pathway, Cell Biol Int. 36:1115-28 (2012)
Nevrivy et al., Interaction of GRASP, a protein encoded by a novel retinoic acid-induced gene, with members of the cytohesin family of guanine nucleotide exchange factors, J Biol Chem 275:16827-36 (2000)
Avram et al., Isolation of a novel family of C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COUP-TF) orphan nuclear receptors, J Biol Chem 275:10315-22 (2000)
Dowell et al., Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein, J Biol Chem 274:15901-7 (1999)
Avram et al., Heterodimeric interactions between chicken ovalbumin upstream promoter-transcription factor family members ARP1 and ear2, J Biol Chem 274:14331-6 (1999)
Dowell et al., p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha, J Biol Chem 272(52):33435-43 (1997)